Showing results (371-380 of 456) with videos related to
Sort By:
Pageof 46
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trialHenry L Y Chan, Scott Fung, Wai Kay Seto, et al.Plos One|February 4, 2021
Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antiviralsChuan-Pin Lin, Po-Cheng Liang, Ching-I Huang, et al.Liver International : Official Journal of the International Association for the Study of the Liver|November 26, 2024
Role of Air Pollution in Development of Hepatocellular Carcinoma Among Chronic Hepatitis B Patients Treated With Nucleotide/Nucleoside AnaloguesTyng-Yuan Jang, Yu-Ting Zeng, Po-Cheng Liang, et al.Clinical and Molecular Hepatology|January 8, 2024
Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patientsJinlin Hou, Edward Gane, Rozalina Balabanska, et al.JHEP Reports : Innovation in Hepatology|January 26, 2024
Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infectionHarry L Janssen, Young-Suk Lim, Hyung Joon Kim, et al.Journal of Clinical and Translational Hepatology|August 14, 2023
Community-centered Disease Severity Assessment of Metabolic Dysfunction-associated Fatty Liver DiseaseJee-Fu Huang, Pei-Chien Tsai, Ming-Lun Yeh, et al.Journal of the Formosan Medical Association = Taiwan Yi Zhi|April 9, 2017
Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohortTa-Wei Liu, Pei-Chien Tsai, Ching-I Huang, et al.Gut|April 22, 2014
Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trialChen-Hua Liu, Chun-Jen Liu, Chung-Feng Huang, et al.Alimentary Pharmacology & Therapeutics|September 27, 2024
Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trialsMaria Buti, Young-Suk Lim, Henry Lik Yuen Chan, et al.Hepatology International|September 25, 2023
Severity of fatty liver is highly correlated with the risk of hypertension and diabetes: a cross-sectional and longitudinal cohort studyChin-I Shih, Kuan-Ta Wu, Meng-Hsuan Hsieh, et al.Pageof 46